Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
European Radiology
Published in: European Radiology 10/2011

01-10-2011 | Magnetic Resonance

Assessing response in bone metastases in prostate cancer with diffusion weighted MRI

Authors: C. Messiou, D. J. Collins, S. Giles, J. S. de Bono, D. Bianchini, N. M. de Souza

Published in: European Radiology | Issue 10/2011

Login to get access

Abstract

Objectives

To determine whether changes in ADC of bone metastases secondary to prostate carcinoma are significantly different in responders compared with progressors on chemotherapy.

Methods

Twenty-six patients with known bone metastases secondary to prostate carcinoma underwent diffusion-weighted MRI of the lumbar spine and pelvis at baseline and 12 weeks following chemotherapy. RECIST assessment of staging CT and PSA taken at the same time points were used to classify patients as responders, progressors or stable. ADC (from b = 0,50,100,250,500,750 smm−2) and ADCslow (from b = 100,250,500,750 smm−2) were calculated for up to 5 lesions per patient.

Results

Mean ADC/ADCslow in lesions from responders and progressors showed a significant increase. Although the majority of lesions demonstrated an ADC/ADCslow rise, some lesions in both responders and progressors demonstrated a fall in ADC beyond the limits of reproducibility.

Conclusions

Mean ADC is not an appropriate measure of response in bone metastases. The heterogeneity of changes in ADC is likely to be related to the composition of bone marrow with changes that have opposing effects on ADC.
Literature
1.
Clamp A, Danson S, Nguyen H, Cole D, Clemons M (2004) Assessment of therapeutic response in patients with metastatic bone disease. Lancet Oncol 5:607–616PubMedCrossRef
2.
Scher HI (2003) Prostate carcinoma: defining therapeutic objectives and improving overall outcomes. Cancer Suppl 97:758–771
3.
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247
4.
Takahara T, Imai Y, Yamashita T, Yasuda S, Nasu S, Van Cauteren M (2004) Diffusion weighted whole body imaging with background body signal suppression (DWIBS): technical improvement using free breathing, STIR and high resolution 3D display. Radiat Med 22:275–282PubMed
5.
Reese TG, Heid O, Weisskoff RM, Wedeen VJ (2003) Reduction of eddy-current induced distortion in diffusion MRI using twice refocused spin echo. Magn Reson Med 49:177–182PubMedCrossRef
6.
Messiou CM, Collins DJ, Morgan VA, deSouza NM (2011) Optimising diffusion weighted MRI for imaging metastatic and myeloma bone disease and assessing reproducibility. Eur Radiol. doi:10.​1007/​s00330-011-2116-4
7.
Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M et al (1999) Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate Specific Antigen Working Group. J Clin Oncol 17:3461–3467PubMed
8.
Lee KC, Bradley DA, Hussain M, Meyer CR, Chenevert TL, Jacobson JA et al (2007) A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the bone. Neoplasia 9:1003–1011PubMedCrossRef
9.
Ballon D, Watts R, Dyke JP, Lis E, Morris MJ, Scher HI et al (2004) Imaging therapeutic response in human bone marrow using rapid whole-body MRI. Magn Reson Med 52:1234–1238PubMedCrossRef
10.
Rozel S, Galbán CJ, Nicolay K, Lee KC, Sud S, Neeley C et al (2009) Synergy between anti-CCL2 and docetaxel as determined by DW-MRI in a metastatic bone cancer model. J Cell Biochem 107:58–64PubMedCrossRef
11.
Lee KC, Sud S, Meyer CR, Moffat BA, Chenevert TL, Rehemtulla A et al (2007) An imaging biomarker of early treatment response in prostate cancer that has metastasized to the bone. Cancer Res 67:3524–3528PubMedCrossRef
12.
Reischauer C, Froehlich JM, Koh DM, Graf N, Padevit C, John H, Binkert CA, Boesiger P, Gutzeit A (2010) Bone metastases from prostate cancer: Assessing treatment response by using diffusion weighted imaging and functional diffusion maps – initial observations. Radiology 257:523–531PubMedCrossRef
13.
Park SH, Kim SJ, Park BC, Suh KJ, Lee JY, Park CW, Shin IH, Jeon IH (2010) Three-dimensional osseous micro-architecture of the distal humerus: implications for internal fixation of osteoporotic fracture. J Shoulder Elbow Surg 19:244–250PubMedCrossRef
14.
Mundinger A, Wiesmeier B, Dinkel E, Helwig A, Beck A, Schulte Moenting J (1993) Quantitative image analysis of vertebral body architecture-improved diagnosis in osteoporosis based on high-resolution computed tomography. Br J Radiol 66:209–213PubMedCrossRef
15.
Morris MJ, Akhurst T, Osman I, Nunez R, Macapinlac H, Siedlecki K, Verbel D, Schwartz L, Larson SM, Scher HI (2002) Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. Urology 59:913–918PubMedCrossRef
16.
Morris MJ, Akhurst T, Larson SM, Ditullio M, Chu E, Siedlecki K, Verbel D, Heller G, Kelly WK, Slovin S, Schwartz L, Scher HI (2005) Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy. Clin Cancer Res 11:3210–3216PubMedCrossRef
Metadata
Title
Assessing response in bone metastases in prostate cancer with diffusion weighted MRI
Authors
C. Messiou
D. J. Collins
S. Giles
J. S. de Bono
D. Bianchini
N. M. de Souza
Publication date
01-10-2011
Publisher
Springer-Verlag
Published in
European Radiology / Issue 10/2011
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-011-2173-8

Other articles of this Issue 10/2011

European Radiology 10/2011 Go to the issue

Neuro

The value of dual-energy CTA for control of surgically clipped aneurysms

Gastrointestinal

Patient acceptability of CT colonography compared with double contrast barium enema: results from a multicentre randomised controlled trial of symptomatic patients

Letter to the Editor

Comment on Cho et al.: Usefulness of FDG PET/CT in determining benign from malignant endobronchial obstruction

Computed Tomography

An education and training programme for radiological institutes: impact on the reduction of the CT radiation dose

Hepatobiliary-Pancreas

The added value of contrast-enhanced ultrasound in patients with colorectal cancer undergoing preoperative evaluation with extensive gadobenate dimeglumine liver MRI

Cardiac

Radiation dose threshold for coronary artery calcium score with MDCT: How low can you go?